Viewing Study NCT01295632


Ignite Creation Date: 2025-12-24 @ 9:46 PM
Ignite Modification Date: 2025-12-29 @ 10:28 AM
Study NCT ID: NCT01295632
Status: COMPLETED
Last Update Posted: 2015-08-27
First Post: 2011-02-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module References Module